Sanofi (NASDAQ:SNY) Receives Consensus Rating of “Buy” from Analysts

Sanofi (NASDAQ:SNY) has received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $61.50.

A number of research analysts recently issued reports on SNY shares. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Morgan Stanley set a $56.00 target price on Sanofi in a report on Monday, June 2nd. Guggenheim reiterated a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Finally, BNP Paribas started coverage on Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company.

Sanofi Trading Down 1.1%

Shares of NASDAQ SNY opened at $47.85 on Friday. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $50.95 and a 200-day simple moving average of $52.02. The stock has a market capitalization of $117.35 billion, a PE ratio of 17.09, a PEG ratio of 0.99 and a beta of 0.50.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion during the quarter, compared to analysts’ expectations of $9.79 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The company’s revenue was down 11.0% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This represents a yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. The ex-dividend date of this dividend was Friday, May 9th. Sanofi’s payout ratio is 57.14%.

Institutional Trading of Sanofi

A number of institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC lifted its holdings in shares of Sanofi by 11.6% in the 1st quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock valued at $11,460,000 after purchasing an additional 21,540 shares during the last quarter. 1248 Management LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at about $518,000. Modern Wealth Management LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at about $205,000. Intrua Financial LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at about $247,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Sanofi by 17.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 11,978 shares of the company’s stock valued at $664,000 after purchasing an additional 1,755 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.